Albendazole negatively regulates keratinocyte proliferation

Clin Sci (Lond). 2020 Apr 17;134(7):907-920. doi: 10.1042/CS20191215.

Abstract

Background: Increased keratinocyte proliferation occurs in the skin of psoriatic patients and is supposed to play a role in the pathogenesis of this disorder. Compounds interfering with keratinocyte proliferation could be useful in the management of psoriatic patients.

Aim: To investigate whether albendazole, an anti-helmintic drug that regulates epithelial cell function in various systems, inhibits keratinocyte proliferation in models of psoriasis.

Methods: Aldara-treated mice received daily topical application of albendazole. Keratinocyte proliferation and keratin (K) 6 and K16 expression were evaluated by immunohistochemistry and Western blotting and inflammatory cells/mediators were analysed by immunohistochemistry and real-time PCR. In human keratinocytes (HEKa and HaCaT) treated with albendazole, cell cycle and proliferation, keratins and cell cycle-associated factors were evaluated by flow cytometry, colorimetric assay and Western blotting respectively.

Results: Aldara-treated mice given albendazole exhibited reduced epidermal thickness, decreased number of proliferating keratinocytes and K6/K16 expression. Reduction of CD3- and Ly6G-positive cells in the skin of albendazole-treated mice associated with inhibition of IL-6, TNF-α, IL-1β, IL-17A, IL-36, CCL17, CXCL1, CXCL2 and CXCL5 expression. Treatment of keratinocytes with albendazole reduced K6/K16 expression and reversibly inhibited cell growth by promoting accumulation of cells in S-phase. This phenomenon was accompanied by down-regulation of CDC25A, a phosphatase regulating progression of cell cycle through S-phase, and PKR-dependent hyper-phosphorylation of eIF2α, an inhibitor of CDC25 translation. In Aldara-treated mice, albendazole activated PKR, enhanced eIF2α phosphorylation and reduced CDC25A expression.

Conclusions: Data show that albendazole inhibits keratinocyte proliferation and exerts therapeutic effect in a murine model of psoriasis.

Keywords: Albendazole; Benzimidazole; drug repurposing/repositioning; keratinocytes; psoriasis.

MeSH terms

  • Albendazole / pharmacology*
  • Animals
  • Cell Line
  • Cell Proliferation / drug effects*
  • Cytokines / genetics
  • Cytokines / metabolism
  • Dermatologic Agents / pharmacology*
  • Disease Models, Animal
  • Eukaryotic Initiation Factor-2 / metabolism
  • Humans
  • Imiquimod
  • Inflammation Mediators / metabolism
  • Keratinocytes / drug effects*
  • Keratinocytes / metabolism
  • Keratinocytes / pathology
  • Keratins / genetics
  • Keratins / metabolism
  • Male
  • Mice, Inbred C57BL
  • Phosphorylation
  • Psoriasis / chemically induced
  • Psoriasis / drug therapy*
  • Psoriasis / metabolism
  • Psoriasis / pathology
  • S Phase Cell Cycle Checkpoints / drug effects
  • Signal Transduction
  • Skin / drug effects*
  • Skin / metabolism
  • Skin / pathology
  • cdc25 Phosphatases / metabolism
  • eIF-2 Kinase / metabolism

Substances

  • Cytokines
  • Dermatologic Agents
  • Eukaryotic Initiation Factor-2
  • Inflammation Mediators
  • Keratins
  • eIF-2 Kinase
  • protein kinase R, mouse
  • Cdc25a protein, mouse
  • cdc25 Phosphatases
  • Albendazole
  • Imiquimod